Related Experiment Video

Updated: May 9, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and

Gaetano Romano1

  • 1College of Science and Technology, Department of Biology, Temple University, Bio Life Science Building, Suite 456, 1900 North 12th Street, Philadelphia, PA 19122, USA.

ISRN Oncology
|July 11, 2013
PubMed

Insights

The cyclin-dependent kinase 9 (CDK9) pathway regulates cell biology and viral replication. Understanding its deregulation in diseases like cancer and AIDS may lead to new kinase inhibitor therapies.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Virology

Background:

  • The CDK9 pathway is crucial for mammalian cell biology and viral replication, including HIV-1.
  • CDK9 exists in two isoforms (CDK9-42 and CDK9-55) that associate with cyclins to form functional heterodimers.
  • These heterodimers are key components of the positive transcription elongation factor b, regulating RNA polymerase II activity.

Purpose of the Study:

  • To review CDK9 pathway deregulation in human malignancies.
  • To explore the development of kinase inhibitors for cancer therapy targeting the CDK9 pathway.
  • To provide insights into the pathogenesis of malignancies, cardiac hypertrophy, and viral diseases.

Main Methods:

  • Literature review of CDK9 pathway deregulation.
  • Analysis of kinase inhibitor development strategies.
  • Classification of kinase inhibitors based on their mechanism of action.

Main Results:

  • Abnormal CDK9 pathway activity is linked to human malignancies and cardiac hypertrophy.
  • Elucidating CDK9 pathway deregulations offers insights into disease pathogenesis.
  • Kinase inhibitors targeting CDK9 can be categorized into ATP-binding site antagonists, allosteric inhibitors, and protein-protein interaction disruptors.

Conclusions:

  • Targeting the CDK9 pathway holds therapeutic potential for cancer, AIDS, and cardiac conditions.
  • Development of specific kinase inhibitors is advancing cancer treatment.
  • Further research into CDK9 pathway deregulations may improve treatments for various pathologies.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...